How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

1 Recommendations

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about lenvatinib with pembrolizumab

Marketing authorisation indication

2.1 Pembrolizumab (Keytruda, MSD), in combination with lenvatinib (Kisplyx, Eisai), is indicated for 'the first-line treatment of advanced renal cell carcinoma in adults'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for lenvatinib and pembrolizumab.

Price

2.3 The price of lenvatinib is £1,437 per 30 4‑mg or 10‑mg capsules (excluding VAT; BNF online accessed July 2022). The price of pembrolizumab is £2,630 per 100 mg per 4‑ml vial (excluding VAT; BNF online accessed July 2022).

The companies have commercial arrangements (simple discount patient access schemes). These make lenvatinib and pembrolizumab available to the NHS with discounts. The sizes of the discounts are commercial in confidence. It is the companies' responsibility to let relevant NHS organisations know details of the discounts.